KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $62.4 million.

  • Supernus Pharmaceuticals' Other Non-Current Assets changed N/A to $62.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.4 million, marking a year-over-year change of. This contributed to the annual value of $31.5 million for FY2024, which is 1593.92% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Other Non-Current Assets of $62.4 million as of Q3 2025.
  • Supernus Pharmaceuticals' 5-year Other Non-Current Assets high stood at $403.8 million for Q1 2023, and its period low was $28.0 million during Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' median Other Non-Current Assets value was $39.3 million (recorded in 2022), while the average stood at $60.1 million.
  • In the last 5 years, Supernus Pharmaceuticals' Other Non-Current Assets soared by 552397.77% in 2021 and then plummeted by 9049.85% in 2024.
  • Supernus Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $49.2 million in 2021, then decreased by 19.15% to $39.8 million in 2022, then dropped by 5.78% to $37.5 million in 2023, then fell by 15.94% to $31.5 million in 2024, then soared by 98.03% to $62.4 million in 2025.
  • Its Other Non-Current Assets was $62.4 million in Q3 2025, compared to $28.0 million in Q2 2025 and $29.2 million in Q1 2025.